Second Affiliated Hospital, Second Military Medical University

Chang-Peng Zhu

Xin Zhang

Wei-Fen Xie

The present invention relates to the technical field of pharmaceuticals and specifically describes an application of a 5-hydroxytryptamine receptor 1A in preparing a drug for portal hypertension. The present invention achieved a significant decrease in portal venous pressure in model rats with cirrhotic portal hypertension by means of an HTR1A inhibitor WAY100635 administered at 1 mg/kg/day by intraperitoneal injection or alverine administered at 15 mg/kg/day by oral gavage. A 5-hydroxytryptamine receptor 1A antagonist can be used to prepare an experimental drug for the treatment of cirrhotic portal hypertension. Furthermore, the 5-hydroxytryptamine receptor 1A antagonist can also be used to prepare drugs for symptoms of portal hypertension syndrome, such as esophageal and fundal varices, rupture and bleeding, ascites, or hepatic encephalopathy. The present invention provides a novel treatment means to treat the manifestations of portal hypertension syndrome, such as esophageal and fundal varices, rupture and bleeding, ascites, or hepatic encephalopathy.

Growing community of inventors

Shanghai, China

Chang-Peng Zhu